Meridian Co., Ltd.
OTC Bulletin Board : MRDAF

Meridian Co., Ltd.

April 05, 2007 14:23 ET

Meridian Signs Distribution Agreement With the University of Natural Medicine for the Sale of Meridian's Digital Pulse Analyzer

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 5, 2007) - Meridian Co., Ltd. ("Meridian" or the "Company") (OTCBB:MRDAF), an industry leader in the research, development, manufacturing and sales of integrative medical equipment, is pleased to announce that its North American distributor, Meridian Medical Inc. ("MMI") has signed a contract with the University of Natural Medicine ("UNM") for the marketing and sales of Meridian's Digital Pulse Analyzer ("DPA").

The UNM has worldwide affiliate clinics and centers in over 15 countries and an International Faculty of over 100 distinguished educators and practitioners. UNM is State Licensed by the New Mexico Higher Education Department as a Private Postsecondary Institution of Higher Learning and has some of the most in-depth and comprehensive programs of integrative and holistic health education available today.

The distribution contract between MMI and the UNM will not only be for sales and marketing of the DPA, but will also include DPA training and certification conducted at the UNM's facilities for medical professionals and students of the University. MMI and the University are in process of conducting a clinical study using the DPA and will present the results of this study and other further studies as they are completed.

In addition, MMI and the UNM are negotiating potential distribution channels throughout the university's worldwide affiliates in 15 other countries which include Russia, England, China, Thailand, Spain, Japan, Costa Rica, and the Bahamas. MMI and the UNM are looking forward to working together to promote the value of incorporating the DPA into a variety of medical modalities and to increase the presence of non-invasive devices that address the importance of preventative cardiovascular screening worldwide.

More About: Digital Pulse Analyzer ("DPA")

The DPA accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA-cleared and Health Canada approved device is inexpensive, non-invasive, and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.

Cardiovascular disease is the number one killer of both men and women in the United States with an estimated economic cost of approximately $298 billion. The Company feels that use of the DPA can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing and sales of advanced medical devices in the healthcare industry. With a dynamic research and development team, Meridian is at the forefront in the development of cutting edge medical technologies. The Company presently holds a total of 18 worldwide patents on its technology, and has received FDA approval and Health Canada approval as well as other international regulatory approvals, for many of its products. Meridian has over 1500 clients including physicians, hospitals, clinics, healthcare professionals, and wellness centers in Korea, USA, Canada, China, Japan and Europe, and continues to successfully market its superior product line to a growing number of clients worldwide.

By continuing its commitment for the globalization and advancement of integrative medical products, Meridian seeks to transform health care from a focus on disease to a focus on wellness and prevention. By working towards this vision, Meridian can ensure it becomes a world-class company for its customers and could ultimately decrease the financial burden placed on the existing, expensive, allopathic health care industry.

On Behalf of the Board of Directors, Hyeon Seong Myeong, President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.

Contact Information